Breast cancer is the most frequent cancer in women, with significant mortality. Mammography is a routine investigation for breast disease. A known risk factor for breast cancer is increased breast density. Here, we tried to observe if mammographic density also affects the hormone receptor status of breast cancer, which will help in the understanding of the biological mechanisms of breast cancer development.

Material and methods:
Suspected breast cancer patients at Lok Nayak Hospital, Delhi, underwent mammography in the Department of Radiodiagnosis. The density of breast contralateral to the mass was assessed using Hologic Quantra software version 2.1.1 [Area Breast Density(ABD)]. The hormone receptor status of all the tumours was recorded on histopathology. Of these, 100 confirmed cases were included in the study.

ER-positive, PR-positive, and HER2-positive tumours were seen in 41%, 33%, and 34% patients, respectively. Regarding ER receptor status, the mean ABD for positive and negative tumours was 27% and 23%, respectively, p-value = 0.01, showing significant relation between them. Mean ABD for HER2-positive and -negative tumours was 25% and 24%, respectively, p-value = 0.75. Mean ABD for PR-positive and PR-negative tumours was 23% and 25%, respectively, p-value = 0.42 (not significant).

We found that ER-positive tumours were common in dense breasts, which was statistically significant. However, this was not true for PR and HER2 receptor status. Limited studies have been done to study MD using computerised software and its effect on hormone receptor status, with conflicting results. Further, large, multicentric studies can be useful in understanding the mechanism and providing better treatment for breast cancer patients.

Edwards BL, Atkins KA, Stukenborg GJ, Novicoff WM, Larson KN, Cohn WF, et al. The association of mammographic density and molecular breast cancer subtype. Cancer Epidemiol Biomarkers Prev 2017; 26: 1487-1492.
Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. J Breast Imaging 2021; 3: 12-24.
Kshirsagar A. QuantraTM 2.2 Software Design Intent and Clinical Performance.
Jeffers AM, Sieh W, Lipson JA, Rothstein JH, McGuire V, Whittemore AS, et al. Breast cancer risk and mammographic density assessed with semiautomated and fully automated methods and BI-RADS. Radiology 2016; 282: 348-355.
Li H, Zhang S, Wang Q, Zhu R. Clinical value of mammography in diagnosis and identification of breast mass. Pak J Med Sci 2016; 32: 1020-1025.
Lian J, Li K. A Review of breast density implications and breast cancer screening. Clin Breast Cancer 2020; 20: 283-290.
Phipps AI, Buist DSM, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. Ann Epidemiol 2012; 22: 340-348.
Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 479-485.
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009; 36: 237-249.
Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. JNCI J Natl Cancer Inst 2011; 103: 1179-1189.
Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K. Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2090-2095.
Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008; 111: 405-410.
Seo BK, Pisano ED, Kuzimak CM, Koomen M, Pavic D, Lee Y, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol 2006; 13: 1211-1218.
Eriksson L, Hall P, Czene K, Dos Santos Silva I, McCormack V, Bergh J, et al. Mammographic density and molecular subtypes of breast cancer. Br J Cancer 2012; 107: 18-23.
Conroy SM, Pagano I, Kolonel LN, Maskarinec G. Mammographic density and hormone receptor expression in breast cancer: the multi­ethnic cohort study. Cancer Epidemiol 2011; 35: 448-452.
Ghosh K, Brandt KR, Sellers TA, Reynolds C, Scott CG, Maloney SD, et al. Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008; 17: 872-879.
Singh N, Joshi P, Gupta A, Marak JR, Singh DK. Evaluation of volu­metric breast density as a risk factor for breast carcinoma in pre- and postmenopausal women, its association with hormone receptor status and breast carcinoma subtypes defined by histology and tumor markers. Egypt J Radiol Nucl Med 2022; 53: 84.
Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP, Jensen MR, Whaley DH, et al. Comparison of clinical and automated breast density measurements: implications for risk prediction and supplemental screening. Radiology 2016; 279: 710-719.
Journals System - logo
Scroll to top